Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Early Anticoagulation With Rivaroxaban Versus Standard of Care in Determining Safety at 365 Days in Symptomatic Cerebral Venous Thrombosis

NCT03178864 is registered in ClinicalTrials.gov with University of British Columbia as lead sponsor.

NCT NCT03178864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03178864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Early Anticoagulation With Rivaroxaban Versus Standard of Care in Determining Safety at 365 Days in Symptomatic Cerebral Venous Thrombosis
Lead sponsor
University of British Columbia
Phase
Phase 2
Overall status
Completed
Start date
March 12, 2019
Completion date
October 5, 2022
Enrollment
55 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral venous thrombosis